239 related articles for article (PubMed ID: 32571580)
1. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
[No Abstract] [Full Text] [Related]
2. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Brownlee W; Bourdette D; Broadley S; Killestein J; Ciccarelli O
Neurology; 2020 Jun; 94(22):949-952. PubMed ID: 32241953
[No Abstract] [Full Text] [Related]
3. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
Carnero Contentti E; Correa J
Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
[No Abstract] [Full Text] [Related]
4. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
[TBL] [Abstract][Full Text] [Related]
5. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile.
Ciampi E; Uribe-San-Martín R; Soler B; Fernández R; García P; Navarrete-Asenjo C; Tirapegui JM; Torres R; Polanco J; Suárez F; Cuello MJ; Cárcamo C
Mult Scler Relat Disord; 2020 Oct; 45():102392. PubMed ID: 32683306
[No Abstract] [Full Text] [Related]
7. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Tomczak A; Han MH
Mult Scler Relat Disord; 2020 Oct; 45():102347. PubMed ID: 32645636
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
Nakamura M; Nakashima I
Brain Nerve; 2020 Oct; 72(10):1079-1083. PubMed ID: 33051396
[TBL] [Abstract][Full Text] [Related]
9. Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
Sastre-Garriga J; Tintoré M; Montalban X
Mult Scler; 2020 Sep; 26(10):1153-1156. PubMed ID: 32552382
[No Abstract] [Full Text] [Related]
10. Immunosuppression drug advice and COVID-19: are we doing more harm than good?
Warraich R; Amani L; Mediwake R; Tahir H
Br J Hosp Med (Lond); 2020 Jun; 81(6):1-3. PubMed ID: 32589546
[TBL] [Abstract][Full Text] [Related]
11. Screening neuromyelitis optica patients for COVID-19 infection.
Mirmosayyeb O; Vaheb S; Barzegar M; Shaygannejad V; Bonavita S; Ghajarzadeh M
Autoimmun Rev; 2020 Nov; 19(11):102669. PubMed ID: 32942032
[No Abstract] [Full Text] [Related]
12. The COVID-19 pandemic and the use of MS disease-modifying therapies.
Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J
Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820
[No Abstract] [Full Text] [Related]
13. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?
Ghajarzadeh M; Bonavita S
Neurol Sci; 2020 Sep; 41(9):2315-2316. PubMed ID: 32638135
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
Racke MK; Newsome SD
J Neuroimmunol; 2020 Aug; 345():577283. PubMed ID: 32518058
[No Abstract] [Full Text] [Related]
15. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
Ciampi E; Uribe-San-Martin R; Cárcamo C
Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203
[No Abstract] [Full Text] [Related]
16. Flattening the anxiety curve: Obstetricians' response to the COVID-19 pandemic in Victoria.
Khot N; Kumar A
Aust N Z J Obstet Gynaecol; 2020 Aug; 60(4):E10. PubMed ID: 32812233
[No Abstract] [Full Text] [Related]
17. Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.
Naser Moghadasi A; Azadvari M; Sahraian MA
Arch Iran Med; 2020 Jul; 23(7):509-510. PubMed ID: 32657605
[No Abstract] [Full Text] [Related]
18. Evaluation of the Level of Anxiety among Iranian Multiple Sclerosis Fellowships During the Outbreak of COVID-19.
Naser Moghadasi A
Arch Iran Med; 2020 Apr; 23(4):283. PubMed ID: 32271605
[No Abstract] [Full Text] [Related]
19. Treatment of multiple sclerosis under the COVID-19 pandemic.
Holmøy T; Torkildsen Ø; Bø L
Tidsskr Nor Laegeforen; 2020 May; 140(8):. PubMed ID: 32463200
[No Abstract] [Full Text] [Related]
20. Neuromyelitis optica spectrum disorder secondary to COVID-19.
Shaw VC; Chander G; Puttanna A
Br J Hosp Med (Lond); 2020 Sep; 81(9):1-3. PubMed ID: 32990089
[No Abstract] [Full Text] [Related]
[Next] [New Search]
